Drug Profile
Beperminogene perplasmid - AnGes
Alternative Names: AMG 0001 01; AMG-0001; Collategene; Hepatocyte growth factor gene therapy - AnGes; HGF Plasmid-AnGesLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AnGes MG
- Developer AnGes; Er-Kim Ilac; Kamada
- Class Antiparkinsonians; Gene therapies; Ischaemic heart disorder therapies; Vascular disorder therapies
- Mechanism of Action Angiogenesis inducing agents; Gene transference; Hepatocyte growth factor expression stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Ischaemic heart disorders; Lymphoedema; Parkinson's disease
Highest Development Phases
- Marketed Chronic limb-threatening ischemia
- Phase II Arteriosclerosis obliterans
- Phase I/II Lymphoedema
- No development reported Ischaemic heart disorders; Parkinson's disease
Most Recent Events
- 31 May 2023 Anges intends to launch beperminogene perplasmid in the US, Europe and Israel
- 31 May 2023 AnGes files MAA for full approval for treatment of patients with chronic arterial occlusionin in Japan
- 03 Mar 2023 AnGes completes enrolment in its phase II trial for Arteriosclerosis obliterans in USA (NCT04267640)